According to our new research study on "Joint Resurfacing Devices Market Forecast to 2031 -Global Analysis - by Type, Material, and End User," the market is anticipated to grow from US$ 2.35 billion in 2024 to US$ 3.25 billion by 2031; the market is expected to register a CAGR of 4.9% from 2025 to 2031. The joint resurfacing devices market growth is attributed to the demographic aging and the global osteoarthritis epidemic. Additionally, advancements in minimally invasive techniques and innovation in next-generation implants contribute to the joint resurfacing devices market growth.

Joint resurfacing is a bone-preserving orthopedic intervention, where the surgeon caps or covers the damaged part of the joint with a smooth implant instead of cutting and removing large portions of bone, as is the case in total joint replacement. The AI-driven precision in joint resurfacing surgeries, smart biomaterials for adaptive joint implants, and telemedicine-enabled remote monitoring for resurfacing recovery are expected to be major joint resurfacing devices market trends in the coming years.

The joint resurfacing devices market in North America is segmented into the US, Canada, and Mexico. The North America joint resurfacing devices market is expanding owing to several factors. The US holds the largest market share, followed by Canada. The demand for joint resurfacing devices in the region is fueled by the advanced healthcare infrastructure, high prevalence of osteoarthritis among an aging population, and widespread adoption of innovative surgical technologies.

Joint resurfacing device market in the US is undergoing a significant transformation to cater to the needs of the elderly population and is also being influenced by the developments in less invasive technologies that are able to preserve the bone stock in younger, more active patients. According to the data from the American Joint Replacement Registry (AJRR), as of 2025, hip resurfacing operations account for only 0.3% of all primary hip arthroplasties. AJRR data depicts the trend for hip and knee procedures from 2012 to 2023 taken from over 4.3 million cases. In other words, the number of hip resurfacing surgeries carried out yearly is somewhere between 1,500 and 2,000, which is a downturn from 3.2% in 2012 and the metal-on-metal wear issue was primarily the reason for the decline but with the ceramic innovations, the numbers are once again increasing.

The Centers for Disease Control and Prevention (CDC) refers to the figure of more than 32.5 million adults with arthritis in the US, pointing out the knee and hip joints as the most affected ones. This trend is what causes a continuous increase of the resurfacing technique as a substitute for total joint replacement. Moreover, the first estimations of the volume of primary total hip arthroplasty imply that at the end of 2025, the hip-joint replacement rates might increase by 75%, and at the same time, the resurfacing method is expected to gain more popularity among patients under 65 years of age.

The Birmingham Hip Resurfacing (BHR) System, certified by the Food and Drug Administration (FDA) in 2011, is an example of the resurface market. The system has been designed for men suffering from severe osteoarthritis and aged between 18 and 60. In the procedure, the femoral head is capped with a metal prosthesis, and the acetabulum is resurfaced, thus, the method allows up to 30% more bone to be saved than in the case of traditional replacements. Another example is the HemiCAP Patello-Femoral Resurfacing Prosthesis that has been cleared by FDA for the purpose of compartmental knee resurfacing and is only used in isolated patellofemoral damage for the most physically active individuals.

The National Institutes of Health (NIH) declared that 90-95% of patients who have undergone resurfacing report being satisfied with the results at five years, and revision risks are lower for patellar resurfacing in total knee arthroplasty (TKAs), where the resurfaced cases have shown a higher survivorship as compared to the non-resurfaced ones.

The Food and Drug Administration (FDA) is invested with regulatory oversight and hence, it is responsible for ensuring strict regulations for pre-market approvals. A 510(k) clearance for a device like the ReCerf all-ceramic hip resurfacing system in 2024 exemplifies the agency's focus on biocompatibility as a measure to address the issue of metal ion release. According to orthopedic registries, the demand for resurfacing in the future is expected to be gradual; however, it will be supported by robotic-assisted precision tools that are capable of cutting down the operative time by 20%. The US market is, in general, a clear indication of shifting toward patient-centered, long-lasting solutions which not only improve the mobility of more than 450,000 hip operations per year but also deal with the issue of fairness in care delivery.

The US Food and Drug Administration, World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), American Association of Hip and Knee Surgeons (AAHKS), and WHO (World Health Organization) are among the primary and secondary sources referred to while preparing the joint resurfacing devices market report.